ErlySign

What ErlySign does

ErlySign (legal entity: CURO Biosciences Pvt Ltd) is a Nagpur, India-based biotechnology company developing saliva-based diagnostic kits for early-stage cancer detection, with its commercial focus on oral precancerous conditions. The company's core product is the ErlySign Oral Cancer Detection Kit — a non-invasive, biomarker-based test that delivers semi-quantitative risk results (Low/Moderate/High) within 15 minutes from a saliva sample. The underlying technology combines hypersialylation biomarker detection with a CRISPR-based RNA biomarker assay (Cas13a/Cas9), supported by peer-reviewed publications and filed/pending patents. A second-generation, CRISPR-based multi-cancer detection kit targeting oral, breast, lung, pancreatic, and colorectal cancers is under development.

The company operates a B2B distribution model, selling kits to three primary institutional customer segments: hospitals, diagnostic labs, and dental clinics across 20+ Indian states. Distribution combines direct enterprise field sales (targeting hospitals and OPD-level screening) with a channel-partner network of diagnostic labs and dental clinics. The kit is positioned at approximately 50% of biopsy cost, requires no refrigeration or lab infrastructure, and is deployable in under 60 minutes of training — economics oriented toward high-frequency, low-friction screening in both urban and rural settings.

ErlySign reports a partner network of 2,500+ across 20+ states, with 500+ hospitals, clinics, and doctors reportedly relying on the kit, 100,000+ screenings conducted, and 10,000+ early-stage oral cancer cases identified. The company has been granted CDSCO approval for large-scale clinical trials (April 2024) and received the US FDA Breakthrough Device Designation in February 2026 — the first saliva-based, non-invasive diagnostic for oral precancerous conditions in India to achieve this status. ErlySign was founded in 2019/2020 by CEO Shubhendra Singh Thakur and CSO Dr. Deovrat Begde, raised Rs 16 crore (~US$1.8M) in pre-Series A funding from Ashish Kacholia in January 2025, and is preparing for full commercial market launch in April 2026.

Name

ErlySign

Legal name

CURO Biosciences Pvt Ltd

Website

https://erlysign.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

ErlySign is a Nagpur, India-based biotech company (CURO Biosciences) that develops and sells saliva-based diagnostic kits for non-invasive, early-stage oral cancer detection, distributing to hospitals, diagnostic labs, and dental clinics across 20+ Indian states.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oral Cancer Screening (HLABAHAF)

akta.pro secondary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Saliva-based diagnostics
• Oral cancer detection
• Molecular diagnostic kits
• Biomarker-based testing
• Early cancer screening

Headquarters

HQ city

Nagpur

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Oral Cancer Detection Kit Sales: ErlySign generates revenue primarily through the sale of its saliva-based oral cancer detection kits to healthcare partners (hospitals, diagnostic labs, dental clinics). Kits are sold as one-time purchase products, with no major infrastructure setup required, enabling recurring purchase cycles as partners deplete test supplies.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

ErlySign develops and sells saliva-based biomarker diagnostic kits for the early detection of oral cancer. Its flagship product is a non-invasive test kit that detects oral precancerous conditions within 15 minutes from a single saliva sample, delivering risk-stratified semi-quantitative results (Low/Moderate/High) with 98.04% clinically validated accuracy. Kits are sold as one-time physical purchases to hospitals, diagnostic labs, and dental clinics across India, with a second-generation CRISPR-based multi-cancer detection platform in development.

Product overview

ErlySign offers a portfolio of saliva-based diagnostic products centered on its core oral cancer detection kit, with future expansion planned through a CRISPR-powered multi-cancer detection platform. The flagship product is a non-invasive, biomarker-based test that detects oral precancerous conditions in 15 minutes using saliva samples, delivering results as risk levels (Low/Moderate/High). The company is developing a second-generation CRISPR-based kit that will screen for five cancer types using the same saliva-based approach.

Differentiator

Problem solved

Functional benefit

Products and services

• ErlySign Oral Cancer Detection Kit A saliva-based, non-invasive diagnostic test kit that detects oral precancerous conditions within 15 minutes using biomarker analysis. The semi-quantitative test assesses risk levels as Low, Moderate, or High and offers 98.04% clinically validated accuracy. The kit is plug-and-play with no lab infrastructure or refrigeration required, enabling deployment in hospitals, diagnostic labs, and dental clinics across urban and rural India.

Quantifiable outcome

• 98% sensitivity and 95–100% specificity in clinical validation trials
• +6 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Healthcare Global (HCG)coreStrategic or Co-development Partner · 11 February 2026Healthcare Global collaborated with ErlySign in clinical trials for the saliva-based oral cancer detection kit. Approximately 1,000 patients participated in trials that demonstrated 98% sensitivity and 100% specificity. HCG is a major Indian cancer care hospital chain.
• Regional Cancer HospitalcoreStrategic or Co-development Partner · 11 February 2026Regional Cancer Hospital collaborated with ErlySign in clinical trials for the saliva-based oral cancer detection kit. Approximately 1,000 patients participated in trials validating the test's effectiveness for early-stage oral cancer risk identification.
• Lumos Health AcceleratorcoreStrategic or Co-development Partner · 12 April 2021Premier healthcare speed scaling program onboarded ErlySign as part of its early cancer detection cohort. Lumos Health Accelerator provides scaling support, mentorship, and network access for high-potential healthtech startups.
• Hospitals, Diagnostic Labs, Dental Clinics Partner NetworkcoreChannel Partner/ Reseller/ DistributorOver 500 hospitals, clinics, and doctors; 2,500+ partners across 20+ Indian states. Partner network enables wide distribution of saliva-based oral cancer screening across urban and rural India. Partners include Sunrise Multispeciality Hospital and multiple dental colleges. Strategic lab partnerships span 5 states.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Salignostics: Israel-based developer of saliva-based diagnostic tests for multiple conditions including cancer. Highly comparable to ErlySign as a fellow saliva-first diagnostics platform pursuing non-invasive early detection, though operating from a different geography.
• OralDNA Labs (by Access Genetics): US-based provider of saliva-based diagnostic testing for oral health, including HPV and oral cancer risk assessment. Closely comparable to ErlySign in using saliva samples for oral cancer/disease risk stratification sold through dental and clinical channels.
• Viome: US-based consumer health company offering saliva-based screening tests, including for early cancer detection. Comparable to ErlySign in the saliva-based diagnostics category and non-invasive early-detection positioning, though operating via a direct-to-consumer model rather than B2B institutional sales.

Broad incumbents

• Guardant Health: US-based liquid biopsy leader with oncology-focused blood-based diagnostic tests (Guardant360, Reveal). Comparable as a non-invasive cancer diagnostics platform; though blood-based rather than saliva-based, it represents the broader category ErlySign's CRISPR multi-cancer platform would compete in.
• Natera: US-based molecular diagnostics company with cell-free DNA and liquid biopsy tests across oncology and reproductive health. Comparable as an established non-invasive molecular diagnostics competitor with commercial scale and pipeline breadth that could overlap with ErlySign's screening use cases.
• Exact Sciences: US-based molecular diagnostics leader best known for Cologuard (stool-based colorectal cancer screening). Comparable as a broadly diversified cancer screening and diagnostics incumbent with established commercial channels, regulatory infrastructure, and capital base that could expand into oral cancer screening.

Emerging players

• VolitionRx: US-based developer of blood-based epigenetic biomarker tests for cancer and other diseases. Comparable as an emerging-stage non-invasive cancer diagnostics company with similar biomarker-based technology and clinical validation trajectory.

Regional players

• Strand Life Sciences: India-based genomics and molecular diagnostics company offering cancer risk assessment and hereditary cancer testing. Comparable as a regional Indian diagnostics peer pursuing genomic/molecular oncology testing, though more focused on genomics than saliva-based rapid screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/erlysign
• LinkedInlinkedin.com/company/curobiosciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ErlySign